Younger Age Is Associated with Improved Survival in Patients Undergoing Liver Transplantation Alone for Metastatic Neuroendocrine Tumors.
Liver transplantation
NET metastases
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
10
03
2020
accepted:
18
06
2020
pubmed:
8
7
2020
medline:
10
7
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Neuroendocrine tumor (NET) metastases are a major cause of morbidity and mortality. The role of liver transplantation to treat unresectable metastases from NET is controversial. We evaluated outcomes of all patients undergoing "isolated" liver transplantation (LT) for metastatic NETs in the USA, from October 1988 through June 2018 using the UNOS dataset. During the study period, 160,360 LTs were performed. Two hundred six adult patients underwent "isolated" LT for metastatic NETs. The mean (SD) age was 48.2 (11.7) years, ranging from 19 to 75 years; 117 (56.8%) patients were male. Overall 1-, 3-, 5-, and 10-year patient survival rates were 89.1%, 75.3%, 64.9%, and 46.1%, respectively. Tumor recurrence was seen in 70 of 206 patients who underwent LT (34%). The median time to recurrence was 28 months (range, 1 to 192 months) and median wait time for LT was 112 days. Tumor recurrence was significantly higher in transplanted patients waiting less than 6 months compared with those waiting more than 6 months (74.3% vs. 25.7%). Patients' age ≤ 45 years had significantly better survival compared with those > 45 years (p = 0.03). Younger patients with carcinoid tumors had better survival but this trend was not observed in the non-carcinoid group. On multivariable analysis, recipient age, donor age, cold ischemic time MELD score, and tumor recurrence were significant predictors of poor patient survival. Waiting time longer than 6 months is associated to lower rates of tumor recurrence. Younger patients ≤ 45 years had significantly improved survival after LT for NET metastases.
Sections du résumé
BACKGROUND
Neuroendocrine tumor (NET) metastases are a major cause of morbidity and mortality. The role of liver transplantation to treat unresectable metastases from NET is controversial.
METHODS
We evaluated outcomes of all patients undergoing "isolated" liver transplantation (LT) for metastatic NETs in the USA, from October 1988 through June 2018 using the UNOS dataset.
RESULTS
During the study period, 160,360 LTs were performed. Two hundred six adult patients underwent "isolated" LT for metastatic NETs. The mean (SD) age was 48.2 (11.7) years, ranging from 19 to 75 years; 117 (56.8%) patients were male. Overall 1-, 3-, 5-, and 10-year patient survival rates were 89.1%, 75.3%, 64.9%, and 46.1%, respectively. Tumor recurrence was seen in 70 of 206 patients who underwent LT (34%). The median time to recurrence was 28 months (range, 1 to 192 months) and median wait time for LT was 112 days. Tumor recurrence was significantly higher in transplanted patients waiting less than 6 months compared with those waiting more than 6 months (74.3% vs. 25.7%). Patients' age ≤ 45 years had significantly better survival compared with those > 45 years (p = 0.03). Younger patients with carcinoid tumors had better survival but this trend was not observed in the non-carcinoid group. On multivariable analysis, recipient age, donor age, cold ischemic time MELD score, and tumor recurrence were significant predictors of poor patient survival.
CONCLUSIONS
Waiting time longer than 6 months is associated to lower rates of tumor recurrence. Younger patients ≤ 45 years had significantly improved survival after LT for NET metastases.
Identifiants
pubmed: 32632728
doi: 10.1007/s11605-020-04708-1
pii: 10.1007/s11605-020-04708-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1487-1493Références
Taal BG aVO. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80:3-7.
doi: 10.1159/000080731
Oronsky B MP, Morgensztern D and Carter C. Nothing but NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991-1002.
doi: 10.1016/j.neo.2017.09.002
Mazzaferro V PA, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplanation? J Hepatol. 2007;47(4):460-466.
doi: 10.1016/j.jhep.2007.07.004
Mayo SC HJ, Cosgrove D, et al. Emerging approaches in the management of patients with neuroendocrine liver metastsis: rile of liver-directed and systemic therapies. J Am Coll Surg. 2013;216:123-134.
doi: 10.1016/j.jamcollsurg.2012.08.027
Rindi G BC, Rappel S, La Rosa S, Stolte M, and Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168-172.
doi: 10.1007/s002689900026
Saeed A BJ, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med. 2013;1(1):6.
pubmed: 25332951
pmcid: 4200695
Yang TX CT, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases- systematic review. Surg Oncol. 2012;21:299-308.
doi: 10.1016/j.suronc.2012.07.001
Taner T AT, Zhang L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB. 2013;15:190-195.
doi: 10.1111/j.1477-2574.2012.00528.x
Sarmiento JM HG, Rubin J, Ilstrup DM, Nagorney DM and Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29-37.
doi: 10.1016/S1072-7515(03)00230-8
Olausson M FS, Herlenius G, et al. Orthoptic liver multivisceral transplantation as treatment of metaststic neuroendocrine tumors. Liver Transpl. 2007.;13:327-333.
doi: 10.1002/lt.21056
Rosenau J BM, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metatstatic neuroendocrine tumors. Transplantation. 2002;73:386-394.
doi: 10.1097/00007890-200202150-00012
Le Treut YP GE, Klempnauer J, et al. Liver transplanation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807-815.
doi: 10.1097/SLA.0b013e31828ee17c
Nguyen NT HT, Goss JA, O'Mahony CA. Neuroendocrineliver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol. 2011:742-890.
Nagorney DM AT, Que FG, Blumgart LH, ed. Hepatic metastases from primary neuroendocrine tumors. In: Surgery of the Liver, Biliary Tract, and Pancreas. 2007:1195-1209.
V. Mazzaferro, C. Sposito, J. Coppa, R. Miceli et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J of Transplantation. 2016;16:2892-2902.
doi: 10.1111/ajt.13831
Gedaly R DM, Davenport D, et al. Liver Transplantation for the Treatment of Liver Metastases From Neuroendocrine Tumors: An Analysis of the UNOS Database. Arch Surg. 2011;146(8):953.
doi: 10.1001/archsurg.2011.186
Alagusundaramoorthy SS GR. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol. 2014;20:14348-14358.
doi: 10.3748/wjg.v20.i39.14348
Hodul P MM, Choi J, et al. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control 2006;13:61-71.
doi: 10.1177/107327480601300109
House MG Cameron J, Lillemoe KD, et al. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145.
doi: 10.1016/j.gassur.2005.05.004
J. Touzios, J. Kiely, S. Pitt et al.. Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery. 2005;241:776-785.
doi: 10.1097/01.sla.0000161981.58631.ab
Yao JC HM, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the Unites States. J Clin Oncol. 2008;26:3063–3072.
doi: 10.1200/JCO.2007.15.4377